Multidisciplinary Team Delivers Comprehensive Options and Evaluates New Treatments for Patients with Low-risk Prostate Cancer
An expert team of urologists, radiologists, radiation oncologists, and medical oncologists at Brigham and Women’s Hospital (BWH) and Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) are providing comprehensive care and studying innovative approaches to evaluate and manage low-risk prostate cancer. “Unlike patients with advanced and aggressive cancers, low-risk prostate cancer may not need to be actively treated. The challenge is determining which patients with low-risk prostate cancer should be treated and what types of treatment are preferable in these cases,” said Adam S. Kibel, MD, Chief of the Division of Urology at BWH and Surgical Director of the Lank Center for Genitourinary Oncology at DF/BWCC.
New Protocol Leads to Shorter Stays and Potentially Better Outcomes after Radical Cystectomies
A new surgical approach at Brigham and Women’s Hospital (BWH) enhances healing and speeds patient recovery following radical cystectomy and urinary diversion, a procedure normally associated with significant morbidity and long hospital stays. “The goal of the evidence-based Enhanced Recovery After Surgery (ERAS) protocol is to reduce length-of-stay and improve patient outcomes after radical cystectomies performed either by open procedure or robotic-assisted technique. The protocol is aimed at decreasing the risk for ileus, surgical site infections, fluid overload, and associated cardiac complications,” explained urologist Mark A. Preston, MD, MPH, Division of Urology at BWH. “The protocol helps the body to heal in the immediate perioperative period by using evidence-based practices to maintain homeostasis and normal body functioning.”
Surgery Provides Overall Survival Benefit in Patients with Advanced Genitourinary Cancers
Urologists and medical oncologists at Brigham and Women’s Hospital (BWH) and Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have led several registry studies demonstrating overall survival benefit in patients with advanced genitourinary cancers, including metastatic urothelial cancer of the bladder and metastatic renal cell carcinoma. Quoc-Dien Trinh, MD, a urologic surgeon in the Division of Urology at BWH and Lank Center for Genitourinary Oncology at DF/BWCC, and Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at DF/BWCC, were senior authors of the studies, which were published in the Journal of Clinical Oncology.